Recent news on Tositumomab

Combo Therapy with Tositumomab Aids Elderly Lymphoma Patients  -  Apr 27, 2007
Cancerpage.com,The patients were given infusions of tositumomab anti-CD20 antibody labeled with tracer for dosimetry purposes, followed 10 days later by individualized

High-Dose Bexxar with Stem Cell Support Effective in Elderly B ...  -  Apr 17, 2007
Cancer Consultants (press release),Researchers from the Fred Hutchinson Cancer Research Center and the University of Washington have reported that high-dose Bexxar (131I-tositumomab) with

Clinical Practice of Molecular Radiotherapy  -  Jan 31, 2007
Journal of Nuclear Medicine (subscription)These articles review the applications of radioimmunotherapy in hematologic malignancies, solid tumors, pediatric malignancies, 131 I-tositumomab in

Hong Song 1 , Yong Du 2 , George Sgouros 1 , Andrew Prideaux 1 ...  -  Jan 4, 2007
Journal of Nuclear Medicine (subscription)90 Y- and 131 I-anti-CD20 antibodies (ibritumomab tiuxetan and tositumomab, respectively) have been approved for the treatment of refractory low-grade

GSK, Genmab Deal Tops All: $2.1B For Phase III Antibody  -  Dec 19, 2006
BioWorld Online,If that happens, Genmab also would get the option co-promote GSK's radiolabeled monoclonal antibody Bexxar (tositumomab, iodine-131) for NHL and Arranon

Collimator Selection, Acquisition Speed, and Visual Assessment of ...  -  Dec 4, 2006
Journal of Nuclear Medicine Technology (subscription)131 I-Tositumomab has been used in treating patients with non-Hodgkin's lymphoma. It is generally recommended that high-energy collimators be used to image

GSK, Genmab Deal Tops All: $2.1B For Phase III Antibody  -  Dec 19, 2006
BioWorld Online,If that happens, Genmab also would get the option co-promote GSK's radiolabeled monoclonal antibody Bexxar (tositumomab, iodine-131) for NHL and Arranon

GSK alliance could give Genmab over £1 billion  -  Dec 19, 2006
Pharma Times (subscription),Genmab may also co-promote GSK's anticancer agents Bexxar (tositumomab and I131) and Arranon (nelarabine) in the USA and the latter drug in Nordic countries

CHOP plus Bexxar® Effective as Initial Therapy in Follicular NHL  Sep 7, 2006
...of Clinical Oncology, treatment with the chemotherapy regimen CHOP followed by the radioimmunotherapeutic agent Bexxar® (I-131 tositumomab) provides long-term ... -Cancer Consultants

Promising Treatment for Some NHL Patients  Sep 5, 2006
...group reported today that 17 patients with advanced follicular non-Hodgkin's lymphoma receiving the experimental treatment of CHOP plus tositumomab/iodine-I ... -Cancerpage.com

Treatment boosts survival in a type non-Hodgkin's  Sep 6, 2006
Those who tolerated the treatment without progression were given the new treatment with iodine I 131 tositumomab, marketed under the trade name BEXXAR® by ... -Cancerfacts.com

Collimator Selection, Acquisition Speed, and Visual Assessment of ...  -  Dec 4, 2006
Journal of Nuclear Medicine Technology (subscription)131 I-Tositumomab has been used in treating patients with non-Hodgkin's lymphoma. It is generally recommended that high-energy collimators be used to image

Medicare to Improve Cancer Patient Care  Jun 30, 2006
...approval. CMS will be announcing continuation of current policies for ibritumomab tiuxetan and tositumomab in the near future. They ... -Cancer Consultants

Regulatory News Article  Jun 30, 2006
3 that Bexxar (tositumomab) "is now indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low grade, follicular, or ... -Cancer Consultants



International Orphan Drug Approvals: 1D09C3 and Nexavar  Apr 21, 2006
...by currently marketed products such as rituximab (Rituxan, made by Biogen Idec), ibritumomab tiuxetan (Zevalin, made by Biogen Idec), and tositumomab/iodine I ... - Medscape (subscription)

Survival Improving for Patients with Stage IV Follicular Lymphoma  Apr 17, 2006
...autologous stem cell transplants and the introduction of monoclonal antibody therapy with Rituxan® (rituximab), Bexxar® (iodine 131 tositumomab) and Zevalin ... - Cancer Consultants

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional